Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERIANNA vs TIROSINT-SOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
Hypothyroidism (all causes, including congenital, primary, secondary, and tertiary),Thyroid-stimulating hormone (TSH) suppression therapy (as an adjunct to surgery and radioiodine therapy for thyroid cancer)
2.5 mg orally once daily
Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
Levothyroxine (T4) terminal half-life: 6–7 days in euthyroid, prolonged in hypothyroidism (9–10 days), shortened in hyperthyroidism (3–4 days). Clinical context: steady-state reached after 4–6 weeks.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Hepatic metabolism via deiodination (D1, D2, D3 isoenzymes; D2 produces T3), glucuronidation (UGT1A), and sulfation; less than 20% excreted unchanged in feces and urine.
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
Renal (biliary/fecal minimal): <20% unchanged in urine; majority metabolized then conjugated and excreted in bile/feces.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin.
0.5-0.7 L/kg, indicating moderate tissue distribution.
0.10–0.15 L/kg; reflects distribution into lean tissues and thyroid hormone receptors.
Oral bioavailability: 60-80%.
Oral: 40–80% (fasting, empty stomach). TIROSINT-SOL liquid formulation has higher relative bioavailability (~90%) compared to tablets.
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
No dose adjustment required for GFR < 60 m L/min; monitor TSH closely in end-stage renal disease as levothyroxine clearance may be reduced.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
No specific Child-Pugh based adjustments; monitor TSH closely in severe hepatic impairment as metabolism may be impaired.
Not approved for pediatric use
Neonates: 10-15 mcg/kg/day orally once daily; Children >1 year: 4-5 mcg/kg/day; Adolescents: 2-3 mcg/kg/day; adjust based on TSH and T4.
No specific dose adjustment; monitor renal function due to age-related decline
Start at lower dose 25-50 mcg/day orally once daily; adjust by 12.5 mcg increments every 4-6 weeks; target TSH 4-6 m IU/L due to higher risk of cardiac effects.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
Not for the treatment of obesity or weight loss; ineffective and dangerous at high doses.
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Cardiac toxicity (arrhythmias, ischemia, palpitations) at high doses; adrenal insufficiency (must be corrected before treatment); worsening angina or congestive heart failure; need for dose adjustment in pregnancy; interactions with warfarin, antidiabetic agents, and other medications.
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
Uncorrected adrenal insufficiency; untreated thyrotoxicosis; hypersensitivity to any ingredient; acute myocardial infarction (relative).
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
Absorption of levothyroxine is reduced by high-fiber foods, soy products, grapefruit juice, and caffeine. Iron, calcium, aluminum- or magnesium-containing antacids, and bile acid sequestrants also inhibit absorption. Separate ingestion of TIROSINT-SOL from these substances by at least 4 hours.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, gestational hypertension, placental abruption, and impaired fetal neurodevelopment. Adequate maternal thyroid hormone levels are critical for fetal brain development, particularly in the first trimester before fetal thyroid function begins.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Levothyroxine is secreted into breast milk in minimal amounts (M/P ratio approximately 2.2). Doses up to 300 mcg/day produce negligible serum levothyroxine levels in breastfed infants. No adverse effects reported. Breastfeeding is considered safe with continued maternal therapy. Monitor infant thyroid function if maternal dose is very high.
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
Pregnancy increases levothyroxine requirements due to increased thyroxine-binding globulin, increased plasma volume, and placental deiodinase activity. Approximately 50-85% of patients require dose increases, often beginning at 4-8 weeks gestation. Starting dose increase: 30-50% increase in levothyroxine dose as soon as pregnancy confirmed. Monitor TSH every 4-6 weeks; adjust in increments of 12.5-25 mcg/day. Postpartum: dose typically returns to prepregnancy level within 4-6 weeks.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
TIROSINT-SOL is a liquid formulation of levothyroxine sodium used for patients who cannot swallow tablets, have GI absorption issues, or require precise dosing. Administer on an empty stomach (30–60 minutes before breakfast) with water only. Avoid administration with iron, calcium, or antacids within 4 hours. Monitor TSH 4–6 weeks after dose changes. Use caution in patients with cardiovascular disease; start with low doses. T4 replacement may unmask adrenal insufficiency in panhypopituitarism—screen with ACTH stimulation test if suspected.
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
Take TIROSINT-SOL exactly as prescribed, usually once daily on an empty stomach, at least 30–60 minutes before eating or drinking anything except water.,Do not mix the solution with any other liquids or foods; only use the provided oral syringe for accurate dosing.,Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding, as dose adjustments may be needed.,Do not stop taking this medication without consulting your doctor, even if you feel well; thyroid hormone replacement is usually lifelong.,Store the solution in the refrigerator (36°F to 46°F) and use within 60 days after first opening; do not freeze.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERIANNA vs TIROSINT-SOL, answered by our medical review team.
CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. TIROSINT-SOL is a Thyroid hormone replacement that works by Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERIANNA and TIROSINT-SOL depend on the specific clinical indication. These are both Thyroid hormone replacement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERIANNA is: 2.5 mg orally once daily. The standard adult dose of TIROSINT-SOL is: Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERIANNA and TIROSINT-SOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. TIROSINT-SOL is classified as Category C. Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is ass. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.